The pericytes may even be the primary endothelial subpopulation at risk.
biorxiv.org/content/10.110…
![](https://pbs.twimg.com/media/EeSVviJWsAEmfGt.png)
nature.com/articles/s4157…
See also:
nejm.org/doi/full/10.10…
sciencedirect.com/science/articl…
A second cut at S2' deploys the fusion protein. For cell-cell fusion, a serine protease at the cell surface does it.
nature.com/articles/s4146…
biorxiv.org/content/10.110…
The virion is pulled into a vesicle by endocytosis of the bound ACE2 receptor, entering an endosome where cathepsins are present.
They cleave S1/S2:
cell.com/iscience/pdf/S…
And S2':
ncbi.nlm.nih.gov/pmc/articles/P…
Cells that do not express such a protease are not, and can only use the endosomal route with free virions.
The reduced latency to infection allows the virus to spread quickly between TMPRSS2+ (or equivalent) cells, even though they are a minority.
Drugs that block endosomal acidification (cathepsins are acid hydrolase enzymes) block endosomal entry.
Drugs that block membrane-associated serine proteases block 'shortcut' cell surface entry and cell-cell fusion.
Wish nafamostat were approved in the U.S. Looks extremely useful.